美通社

2024-09-10 20:00

Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024

GAITHERSBURG, Md., Sept. 10, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at 10:00 a.m., Beijing time, on September 27, 2024, virtually via a Zoom video conference call, for the purpose of considering and, if thought fit, passing the proposed resolutions set forth in the notice of EGM (the "Notice of EGM").

Instructions for accessing the video conference call are as follows:

Zoom Meeting URL: https://us06web.zoom.us/j/6195900008?pwd=OTEvOGtnNFVpaUdBUkdRRlp4Y0txUT09

Meeting ID: 619 590 0008

Passcode: 666666

The purpose of the EGM is for the Company's shareholders to approve several resolutions in relation to regaining compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1) prior to the expiration of the grace period on October 21, 2024, including (i) with effect from October 1, 2024, to consolidate every 10 (ten) ordinary shares, par value of US$0.00002 each (whether issued or unissued), into 1 (one) ordinary share, par value of US$0.0002 each (the "Share Consolidation"); and (ii) with effect immediately following the Share Consolidation, to amend and restate the currently effective memorandum and articles of association of the Company by their deletion in their entirety and the substitution in their place of the second amended and restated memorandum and articles of association of the Company.

The close of business on September 11, 2024 (Eastern Time) has been fixed as the record date of the EGM. Holders of record of the Company's ordinary shares as of the record date shall be entitled to attend and vote at the EGM virtually and any adjourned meeting thereof. The Notice of EGM and proxy card for the EGM are available on the Company's website at investor.lakeshorebio.com. The board of directors of the Company fully supports the proposed resolutions listed in the Notice of EGM and recommends that shareholders vote in favor of the resolutions set out in the Notice of EGM. 

About LakeShore Biopharma

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.lakeshorebio.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of LakeShore Biopharma, the development progress of all product candidates, the progress and results of all clinical trials, LakeShore Biopharma's ability to source and retain talent, and the cash position of LakeShore Biopharma. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "potential," "forecast," "intend," "will," "expect," "anticipate," "believe," "goal," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of LakeShore Biopharma's management and are not predictions of actual performance.

LakeShore Biopharma cannot assure you the forward-looking statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading "Risk Factors" in the company's Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, and other risks described in documents subsequently filed by the company from time to time with the SEC. There may be additional risks that LakeShore Biopharma does not presently know or that LakeShore Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of LakeShore Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while LakeShore Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of LakeShore Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, LakeShore Biopharma does not undertake any duty to update these forward-looking statements.

Investor Relations Contact

Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: LakeShoreBiopharma.IR@icrinc.com 

source: LakeShore Biopharma Co., Ltd

【你點睇?】DeepSeek發布受到關注,惟美國正調查其有否透過第三方購入先進晶片,你認為美方會否封鎖DeepSeek?► 立即投票

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
4
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
5
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
6
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
7
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
8
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
9
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
10
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
11
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
12
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
13
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
14
一本萬利 | 2025年的五個「勿」(有片)
15
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
16
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
17
高息定存 | 一周高息合集,銀行高息吸客,低門檻10萬享6.18厘,3個月最高5厘
18
港股 | 蕭猷華:恒指春節前目標21500點
19
財政預算案2025 | 羅兵咸料本財年財赤948億,財政儲備降至紀錄新低
20
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
21
神州經脈 | 基金賣股票據報受限,滬指連跌四日,人行穩匯率
22
習近平應約與特朗普通電話,特:冀盡快與習見面
23
加州山火 | 美國洛杉磯大火失控,被迫撤離人數增至18萬
24
【FOCUS】去年貿易順差破紀錄,中國擴消費增緊迫感
25
【FOCUS】侵侵就職倒數一周,美元及油價劇本臨揭盅
26
加州山火造成超500億美元損失,大量房主未買保險
27
賣地計劃 | 政府今季推一幅東涌住宅地涉745伙,全年供應不達標
28
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
29
雷賢達觀點 | 香港篇:恒指年波幅料六千點,港須全面融入大灣區
30
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老